Transcode Therapeutics
NASDAQ: RNAZBoston, US · Delaware corporation
TransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Founders & leadership
TA
Thomas A. FitzgeraldExecutive
Board
MM
Magda MarquetBoard director
EM
Erik MantingBoard director
PC
Philippe CalaisBoard director
Reported raises · per SEC filings
Form D private placements$8M disclosed across 1 round · 2024
▶$8MraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
▶$8MraisedDec 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Magda MarquetDirector
- Erik MantingDirector
- Thomas A. FitzgeraldExecutive Officer, Director
- Philippe CalaisDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $320K
- Placement agents
- The Benchmark Company LLC, A.G.P./Alliance Global Partners
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld122 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Day One Biopharmaceuticals81 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Companies competing with Transcode Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Transcode Therapeutics do?
- TransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
- How much funding has Transcode Therapeutics raised?
- Transcode Therapeutics has disclosed $8M raised across 1 round.
- Where is Transcode Therapeutics headquartered?
- Transcode Therapeutics is headquartered in Boston, US.